Meta Ads for Longevity, Peptide Therapy & IV Therapy Clinics.
Longevity is the hardest Meta vertical we run. The audience is biohacker-educated, reflexively ad-skeptical, and convinced most longevity marketing is snake oil. "Longevity" barely appears in Meta's interest taxonomy. And the FDA has restricted most of the peptides you want to market. The program that works runs podcast-clip creative, provider-authority funnels, and 90+ day retargeting — it looks nothing like a med spa or functional medicine Meta campaign.
$5,000/mo retainer floor · Calendly-first booking · Founder reviews every inquiry personally.
Facebook vs. Instagram creative allocation
~70 / 30
longevity audience skews older and consumes long-form content more than short-form — Facebook feed and Facebook-video outperform Reels for this vertical, opposite of the med spa pattern
Cost per booked consultation
$300–$800
the highest in our vertical set — the audience is hardest to reach at scale, the creative requires production time, and the consideration cycle is longest (3-6 months from first touch to consult)
Standard retargeting window
90+ days
longest in our Phase-2 set. Biohacker patients research a clinic across podcast episodes, Substack posts, peer conversations, and a string of Meta touches over 3-6 months before they book — attribution has to stretch that far
Three structural problems no other subtype faces simultaneously.
Longevity is the hardest Meta vertical in our entire Phase-2 umbrella, and we say that with specifics. Three structural problems compound on each other, and none of them have clean fixes — only discipline and patience. A clinic that launches a longevity Meta program expecting med-spa economics or TRT-style patient volume burns budget and concludes incorrectly that "Meta doesn't work for longevity." Meta works; the program just has to respect what's actually hard about the category.
Problem one: the audience is ad-skeptical by identity. A biohacker who follows Huberman, Attia, Asprey, or Rhonda Patrick has been trained to recognize and discount health marketing as a category. A polished, direct-response Meta ad is exactly the thing this audience has learned to mistrust. The creative has to look and feel NOT like an ad — closer to a podcast clip, a provider explaining something they'd explain on a podcast, or a deeply-cited article than to anything resembling scroll-stopping DTC creative.
Problem two: "longevity" barely exists as a category in Meta's interest taxonomy. Meta has broad health-and-wellness interest targeting, functional-medicine-adjacent targeting, biohacking mentioned occasionally, but "longevity" as a buyer category is poorly indexed. Meta's own interest-based audience for longevity terms is thin and noisy — you can target it but you'll spend half your budget on people who aren't actually the buyer. Audience-building has to rely more heavily on lookalikes from existing patients (HIPAA-carefully sourced) and on interest-adjacency from closely-associated podcasters and brands.
Problem three: the treatments face the tightest FDA / Meta policy intersection in the umbrella. Compounded peptides (BPC-157, thymosin alpha-1, CJC-1295, ipamorelin) moved to Category 2 or restricted in 2023-2025. Exosomes face FDA warning-letter history. NAD+ IV has FTC substantiation exposure. Meta's Prescription Drugs policy applies to some of these. Ad copy written in 2022 about these modalities is now a compliance liability and Meta is likely to flag it on review. The program has to know the current FDA status of every modality it's promoting, every month.
Podcast-clip creative. Provider-authority funnels. 90+ day retargeting.
A longevity Meta program that actually works has three pillars, and none of them come from the DTC Meta playbook. Podcast-clip-style creative (not polished ads). Provider-authority funnels running webinar and long-form article assets. And 90+ day retargeting windows because the audience takes months to convert. Here's how each layer is built.
Podcast-clip creative production
Your provider on camera for 3-15 minutes explaining a specific modality, protocol, or finding — shot with podcast-production aesthetic (not studio polish), captioned for sound-off autoplay, exported as Facebook-video-friendly long-form plus shorter cuts for Reels. This format matches how the audience already consumes health content.
Webinar + long-form article funnels
Parallel to functional medicine but with a different tone. Webinars emphasize clinical rigor and mechanism of action rather than empathic patient-journey framing. Landing articles cite the primary research and discuss protocol reasoning at the level the audience reads. Goal: earn enough trust that the audience commits to the consultation.
Lookalike + podcast-adjacency targeting
Meta's longevity interest taxonomy is thin. We build audiences via HIPAA-sourced lookalikes from your existing patients plus interest-adjacency targeting (Huberman Lab interests, Peter Attia adjacency, Ben Greenfield audiences where available, biohacking communities). Plus geo-income for the affluent tier that enrolls in multi-modality protocols.
FDA-status-aware creative library
Every piece of creative that references a peptide, exosome product, or NAD+ variant is checked against current FDA status — Category 1 / Category 2 / restricted / warning-letter history. Content gets re-audited monthly because the FDA posture moves. Ad copy that was fine in 2022 may not be fine now.
90+ day retargeting architecture
The biohacker's research cycle is 3-6 months minimum. Standard 30-day retargeting pools exhaust before the buyer is ready. We build 90-180 day retargeting windows with creative rotation — different provider, different modality, different angle every 3-4 weeks — so the audience sees 10-15 substantive touches before the consult CTA ever fires.
Podcast-placement + Meta funnel integration
Meta isn't the only discovery channel for this audience — podcasts are. We integrate Meta creative with podcast-placement efforts (clips of your provider on podcasts your audience already listens to, retargeted to podcast-listener lookalikes). The full program's return is larger than Meta's in isolation.
Four structural realities that no other subtype faces.
Longevity Meta doesn't borrow cleanly from any other vertical's playbook. The TRT Meta rules (competing with national brands, symptom-adjacent creative) don't apply because there are no dominant national longevity brands running Meta ads — the channel is actually under-saturated. The med spa Meta playbook doesn't apply because the creative aesthetic is opposite. The functional medicine Meta playbook is closest but still differs in tone and audience psychology. Four specific realities below.
Meta's interest taxonomy barely has "longevity" as a category
Longevity as a buyer category is poorly indexed in Meta's audience data. The interests exist but are thin and noisy — you can target them but you'll waste spend on non-buyers. Audience-building has to lean harder on lookalikes and podcast-adjacency than on standard interest targeting. This is category-specific; functional medicine, by contrast, has rich interest targeting available.
Polished production underperforms podcast-clip rawness
Biohacker audiences have been trained to discount polished health ads. Counterintuitively, a phone-shot 8-minute provider explainer routinely outperforms a $20k studio-produced creative spot on this audience. The quality signal the biohacker reads is provider depth, not production polish. We produce accordingly.
FDA peptide restrictions create per-modality creative mapping
BPC-157 creative has different compliance requirements than NAD+ creative has different compliance requirements than exosome creative. Each modality's current FDA status determines what the ad can claim and how the landing page can position it. We maintain a modality-by-modality compliance map and re-audit it monthly.
The biohacker is actively ad-skeptical — earn attention, don't buy it
This audience has spent years filtering health marketing. A direct-response frame doesn't just underperform — it actively signals the brand is untrustworthy. The creative has to earn the watch-through by demonstrating depth, not by stopping the scroll with shock or urgency. This inverts a lot of standard Meta best practice.
Modality compliance map → podcast-clip library → webinar build → long-cycle launch.
This is the longest ramp of any Meta engagement in our umbrella — typically 45-60 days from kickoff to first live campaign — because both the creative and the audience-building take more work than in other subtypes. The program compounds well once it's running, but resist the urge to shortcut the ramp.
- Step 01
Discovery + FDA peptide/modality audit
30-minute discovery plus a mapping of every modality your clinic currently offers against current FDA status (Category 1 / Category 2 / restricted / warning-letter history). Output: which modalities can be featured in creative, which belong on the landing page only, which require specific disclaimers, and which should not be advertised at all under current rules.
- Step 02
Podcast-clip creative library production
4-8 pieces of provider-led long-form video (3-15 minutes each), shot in podcast-production aesthetic. Each piece covers a specific modality or clinical topic in depth. Captioned, sound-off optimized, exported in Facebook-video and Reels-cut formats. This library is the engine of the program.
- Step 03
Webinar build + landing-article content
A 60-90 minute clinical-rigor webinar on your clinical framework (different tone from functional medicine — emphasize mechanism and evidence, not empathy). Plus 3-5 long-form landing articles (1,500-3,500 words) with full citations. These are the conversion assets the Meta creative drives to.
- Step 04
Audience build — lookalikes + podcast adjacency + HIPAA compliance
Lookalikes from existing patient list (HIPAA-sourced, hashed uploads through BAA-compliant CRM). Podcast-adjacency targeting (Huberman, Attia, Asprey, Greenfield audience interests). Geo-income for affluent multi-modality-program enrollees. Explicit HIPAA workflow documentation in the engagement SOP.
- Step 05
Launch with 90-day attribution from day one
Opening budget modest ($5k-$15k over 30 days). CAPI + CRM source-tagging with 90-day view-through attribution baked in from launch. The program will look inefficient on 7-day metrics; we report on 90-day windows because that's when the actual conversions land.
- Step 06
Monthly FDA-status re-audit + creative refresh
Monthly: re-audit every modality referenced in creative against current FDA status, refresh creative ahead of fatigue, review which podcast-adjacency audiences are performing. Quarterly: retire old modules that have drifted, produce the next batch of podcast-clip creative, review program-health against enrolled-patient numbers.
Enrolled protocol patients, content-engagement depth, and compliance coverage.
Consult bookings alone misread longevity Meta programs because of the long consideration cycle and the program-enrollment revenue model. We report on enrolled protocol patients (revenue), content engagement depth (leading indicator), and FDA-status compliance coverage (risk-management metric).
Enrolled protocol patients (90-day attribution)
The revenue metric. Tracked with CRM source-tagging back to the originating Meta touchpoint. Longevity patients enroll in multi-modality protocols — the number that matters is enrolled patients, not booked consults.
Content engagement depth on long-form creative
Watch-time on 3-15 minute video assets, read-through on landing articles, webinar attendance rate and retention. These engagement metrics predict consult bookings 6-12 weeks out. They're the earliest signal that the creative is landing with the right audience.
Cost per enrolled protocol patient
Full-program unit economic. Meta spend / enrolled protocol patients. Benchmarked against your clinic's first-year protocol revenue (typically $5,000-$25,000 depending on modality mix) so the CAC-to-LTV math is visible monthly.
FDA-status compliance coverage
Internal risk metric: percentage of active creative whose modality references reflect current FDA status (vs. stale 2022-2023 wording). Target 100%. This is where most longevity Meta programs that run without a specialist develop exposure.
Illustrative metrics. Individual clinic results vary by market, intake capacity, and baseline. No guaranteed outcomes — standard FTC endorsement disclaimers apply.
The tightest policy stack in the umbrella — four active surfaces.
Longevity Meta advertising lives at the intersection of the most actively-changing regulatory landscapes in our umbrella. The FDA has been tightening compounded-peptide rules since 2023. The FTC has been active on longevity-outcome substantiation. Meta's Prescription Drugs policy applies to some modalities. And the individual modalities (BPC-157, TA-1, CJC-1295, exosomes, NAD+) each carry their own compliance surface. A campaign compliant last quarter may not be compliant this quarter.
Four guardrails below are the ones we audit on every creative, every month.
Compounded-peptide FDA Category 2 status
BPC-157, thymosin alpha-1, CJC-1295, ipamorelin and others shifted to Category 2 or restricted between 2023-2025. Ads that imply broad availability or equivalence to FDA-approved products are exposed. We audit the FDA 503A / 503B compounding status monthly and re-check creative against it.
Exosome FDA warning-letter history
The FDA has issued warning letters to clinics and suppliers marketing exosome products as treatment or cure for specific conditions. Ad claims must avoid treatment/cure language and reflect the specific FDA regulatory posture on exosomes. We write to this line on every exosome-referencing creative.
NAD+ IV FTC substantiation exposure
Claims like "reverses aging," "extends cellular lifespan," "repairs DNA damage" — attached to NAD+ IV advertising — require FTC Section 5 substantiation. Most 2022-era NAD+ marketing copy does not meet the standard. We rewrite to substantiable mechanism-and-approach language.
Meta Prescription Drugs policy application
Some peptides and IV modalities trigger Meta's Prescription Drugs policy (additional review, required disclosures, restricted targeting). We track which modalities trigger the policy on Meta's current posture and structure creative accordingly — some modalities land on the landing page only, not in ad copy.
Common questions.
- Can we run Meta ads for peptide therapy at all given FDA restrictions?
- Yes, with significant care. The FDA's 2023-2025 restrictions on compounded peptides (BPC-157, thymosin alpha-1, CJC-1295, ipamorelin and others) narrowed what can be freely marketed. Your clinic's legal basis for prescribing each peptide determines what ad copy is possible. The pattern that works: broader-frame creative ("peptide therapy for longevity protocols") in the ad, specific-modality details on the compliant landing page. Some peptides may not be advertisable at all under current rules — we tell you on the discovery call after reviewing your clinic's current prescribing posture.
- Meta's ad library shows almost no longevity ads. Is the channel even viable for this audience?
- Yes — and the under-saturation is actually an advantage. Because few clinics run longevity Meta programs competently, CPMs stay reasonable and the feed isn't saturated with competing messages. The channel works; it just requires a category-appropriate creative approach (podcast-clip style, provider-authority funnels, 90+ day retargeting) that most agencies don't know to use. Clinics that get the approach right have a clear lane.
- How do podcast-clip-style ads perform vs. traditional polished creative?
- Podcast-clip outperforms polished on this audience by a wide margin in our account data. The biohacker audience has been trained to discount polished health ads — they read polish as a marketing tell. An 8-minute phone-shot provider explaining a protocol, with subtitles and basic production, routinely generates 3-5x the watch-time and 2-3x the booking conversion of a $20k studio-produced creative. The audience is buying provider depth, not production quality.
- What does a webinar-to-consult funnel look like for a longevity audience?
- Similar structure to functional medicine's but with a different tone. The webinar emphasizes clinical rigor, mechanism of action, protocol reasoning, and primary-research citation — rather than the empathy-and-journey framing that works for functional medicine's post-conventional-care audience. Duration 60-90 minutes. Registration landing page with consent-compliant capture. Post-webinar retargeting differentiated by engagement depth (attended + engaged / attended / registered-only). Consultation ads only fire to the deepest-engaged cohort.
- How do we target biohackers when Meta's interest taxonomy is thin for this?
- Three-part approach. First, lookalikes from your existing enrolled-patient list (HIPAA-sourced, hashed through BAA-compliant CRM integration). Second, podcast-adjacency interests where Meta has them — Huberman Lab audiences, Peter Attia adjacency, Ben Greenfield audience, biohacking communities. Third, geo-income proxies for the affluent multi-modality-protocol enrollee. No single layer is sufficient; the combination reaches the intended audience.
- Why Facebook over Instagram for longevity?
- The longevity audience skews 40-60 and consumes long-form video more patiently than the Reels-native demographic. Facebook Feed and Facebook Video handle 3-15 minute content better than Instagram Reels does — Reels' short-form default cuts off the longevity creative that actually converts. We allocate roughly 70% Facebook / 30% Instagram on most longevity accounts, opposite of the med spa pattern (where Reels-first works). Not a hard rule — we test on each account — but it's been consistent across our book.
- How do we attribute a 90-day consideration cycle?
- 90-day view-through attribution on the Meta side, CRM-level source-tagging on the clinic side. Meta's default 7-day or 28-day attribution windows systematically undercount longevity programs by 50-70%. We set the pixel + CAPI to 90-day view-through from day one, and source-tag every consult booking in the CRM so the longest-cycle patients get attributed to the originating Meta touch. Without this, a working longevity program looks unprofitable on the first 60 days of reporting.
Pair this with the rest of the six-surface playbook.
The paired page
SEO for Longevity Clinics
The organic-search side — modality-first content architecture, FDA peptide-status tracking, biohacker-ecosystem integration (Huberman / Attia / Asprey / Greenfield podcast placement). Pairs with the Meta program; the podcast-adjacency work compounds across both channels.
Meta Ads for TRT Clinics
Compliant Facebook & Instagram ads for TRT and men's health.
Learn more
Meta Ads for Anti-Aging Clinics
Facebook & Instagram ads for anti-aging and age management.
Learn more
Meta Ads for Functional Medicine
Facebook & Instagram ads for functional and integrative medicine.
Learn more
Ready to run Meta for an audience that's already seen every health ad you can name?
Book a 30-minute discovery call. We'll map your modality menu against the current FDA compliance picture, review your audience-build options under Meta's thin longevity taxonomy, and show you what a podcast-clip-first creative library looks like — whether you hire us or not.